-+ 0.00%
-+ 0.00%
-+ 0.00%

Zhitong Finance App News, Weilizhibo-B (09887.HK) issued an announcement. Velisin™ (PD-L1/4-1BB bispecific antibody opatisumimab, LBL024) biological product marketing license application (BLA) for treating advanced extrapulmonary neuroendocrine cancer has been approved by the National Drug Administration (NMPA) Drug Evaluation Center (CDE) of the People's Republic of China for inclusion in the priority review and approval process. This BLA report is based on the positive results of a key registered clinical study led by Professor Shen Lin of Beijing Cancer Hospital to evaluate the efficacy and safety of Velisin™ in advanced EP-NEC patients who have previously received second-line or higher systematic treatment.

Zhitongcaijing·07/10/2026 04:41:03
Listen to the news
Zhitong Finance App News, Weilizhibo-B (09887.HK) issued an announcement. Velisin™ (PD-L1/4-1BB bispecific antibody opatisumimab, LBL024) biological product marketing license application (BLA) for treating advanced extrapulmonary neuroendocrine cancer has been approved by the National Drug Administration (NMPA) Drug Evaluation Center (CDE) of the People's Republic of China for inclusion in the priority review and approval process. This BLA report is based on the positive results of a key registered clinical study led by Professor Shen Lin of Beijing Cancer Hospital to evaluate the efficacy and safety of Velisin™ in advanced EP-NEC patients who have previously received second-line or higher systematic treatment.